Evidence map›Paper›PMID 30755985›Full record

ArticleEuropean journal of case reports in internal medicine2018

A Low Rivaroxaban Plasma Level May Indicate Anticoagulation Undertreatment.

Simone Lorenzo Romano, Paolo Chiarugi, Monica Casini, Giovanni Pellegrini, Lucia Ruocco

Abstract read
In one paragraph

Article in European journal of case reports in internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Simone Lorenzo RomanoDepartment of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Paolo ChiarugiClinical Chemistry Laboratory, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.
Monica CasiniClinical Chemistry Laboratory, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.
Giovanni PellegriniClinical Chemistry Laboratory, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.
Lucia RuoccoClinical Chemistry Laboratory, Department of Laboratory Medicine, University Hospital of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Few reports have been published on the correlation between plasma concentrations of rivaroxaban and clinical outcome in patients who have experienced venous thromboembolism. This article describes the case of a 44-year-old woman who experienced deep vein thrombosis during anticoagulation therapy with rivaroxaban, with evidence of repeated low plasma levels of the drug. We postulate that the determination of plasma rivaroxaban anti-Xa activity can be useful in the evaluation of anticoagulation therapy in selected cases. LEARNING POINTS: Some patients with deep vein thrombosis do not respond to rivaroxaban therapy.Accurate determination of rivaroxaban plasma concentrations is important in clinical practice.The clinical value of rivaroxaban plasma concentrations might be limited by intra- and inter-individual variations.

Indexed as

anti-Xa assaysrecurrent venous thrombosisRivaroxaban

Identifiers

PMID30755985
PMCPMC6346803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.